SGS Expands Biopharma Testing Capabilities in Geneva


New lab to offer a full ICH Q6B physico-chemical characterization of biologics

SGS is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with a new 200m2 lab. The lab will be equipped with a number of new instruments to help meet the growing need for biopharmaceutical studies during the early and late phase of characterization, as required by the ICH guidelines.
Scheduled to open in 3Q18, the new lab will offer services for high order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC).
“To fulfil regulatory requirements, the biopharmaceutical industry increasingly expects its contract service providers to offer comprehensive characterization capabilities from a single location,” said Luc-Alain Savoy, managing director SGS Life Sciences Geneva. “SGS is committed to investing in its network of laboratories to offer integrated solutions and adapt to its clients’ local and global needs.”
When complete, the new lab will enable the Geneva facility to offer a full ICH Q6B physico-chemical characterization of biological products.